AEGiS-GMHC: Treatment Briefs: Glaxo Buys in

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Treatment Briefs: Glaxo Buys in

Treatment Issues, Volume 12, Number 5 - May 1998
Dave Gilden

While Upjohn moves to reduce its presence in the HIV arena, Glaxo just gets in deeper. The company already has two new antiretrovirals, abacavir and amprenavir, that will reach the market by the end of this year. In addition, it recently bought a family of sturcturally related NNRTIs from Hoechst Marion Roussel to complete its anti-HIV product range.

The original lead NNRTI was HBY 097, which has already been tested in a small number of humans and looked very good in its initial run-through. Viral load drops of greater than one log (90%) after 14 days of monotherapy were observed, without the appearance of drug-resistance mutations in participants' HIV. During a 1996 interview with Treatment Issues, famed HIV drug discoverer Eric DeClercq said of HBY 097, "It's... within the top few compounds that we have analyzed ourselves. I hope it will be developed."

But development of HBY 097 was in fact terminated. The compound's short half-life in the body and large required dose led to an onerous dosing schedule and concerns about possible toxicities and interactions with other drugs. Glaxo is now starting back at the beginning with the compounds, evaluating candidate NNRTIs for anti-HIV activity and drug-resistance profiles.

980501
GM120507

Copyright © 1998 - Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, Inc. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 fredg@gmhc.org http://www.gmhc.org

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .